Any feedback?
Literature summary for 3.4.16.2 extracted from
- Human prolylcarboxypeptidase (1981), Methods Enzymol., 80, 460-466.
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| diisopropyl fluorophosphate | 1 mM, complete inhibition | Homo sapiens |  |
| pepstatin | 0.3 mM, complete inhibition | Homo sapiens | |
| phenylmethylsulfonyl fluoride | 1 mM, complete inhibition | Homo sapiens | |
KM Value [mM]
| KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
|---|---|---|---|---|---|
| 0.77 | - |
N-benzyloxycarbonyl-Pro-Phe | - |
Homo sapiens | |
| 1 | - |
angiotensin II | - |
Homo sapiens | |
| 2 | - |
angiotensin III | - |
Homo sapiens | |
Molecular Weight [Da]
| Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
|---|---|---|---|
| 45000 | - |
x * 45000 + x * 66500, SDS-PAGE in presence of 2-mercaptoethanol | Homo sapiens |
| 66500 | - |
x * 45000 + x * 66500, SDS-PAGE in presence of 2-mercaptoethanol | Homo sapiens |
| 115000 | - |
gel filtration | Homo sapiens |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Source Tissue
| Source Tissue | Comment | Organism | Textmining |
|---|---|---|---|
| blood | - |
Homo sapiens | - |
| fibroblast | - |
Homo sapiens | - |
| kidney | - |
Homo sapiens | - |
| lung | - |
Homo sapiens | - |
| lymphocyte | - |
Homo sapiens | - |
| macrophage | - |
Homo sapiens | - |
| polymorphonuclear leukocyte | - |
Homo sapiens | - |
| urine | - |
Homo sapiens | - |
Specific Activity [micromol/min/mg]
| Specific Activity Minimum [µmol/min/mg] | Specific Activity Maximum [µmol/min/mg] | Comment | Organism |
|---|---|---|---|
| 0.51 | - |
- |
Homo sapiens |
Substrates and Products (Substrate)
| Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| angiotensin II + H2O | about 35% of the activity with angiotensin III | Homo sapiens | ? | - |
? | |
| angiotensin III + H2O | - |
Homo sapiens | ? | - |
? | |
| N-benzyloxycarbonyl-Pro-Ala + H2O | 33% of the activity with angiotensin III | Homo sapiens | N-benzyloxycarbonyl-Pro + Ala | - |
? | |
| N-benzyloxycarbonyl-Pro-Leu + H2O | 12% of the activity with angiotensin III | Homo sapiens | N-benzyloxycarbonyl-Pro + Leu | - |
? | |
| N-benzyloxycarbonyl-Pro-Phe + H2O | 8% of the activity with angiotensin III | Homo sapiens | N-benzyloxycarbonyl-Pro + Phe | - |
? | |
| N-benzyloxycarbonyl-Pro-Ser + H2O | 7% of the activity with angiotensin III | Homo sapiens | N-benzyloxycarbonyl-Pro + Ser | - |
? | |
| N-benzyloxycarbonyl-Pro-Val + H2O | 28% of the activity with angiotensin III | Homo sapiens | N-benzyloxycarbonyl-Pro + Val | - |
? | |
Subunits
| Subunits | Comment | Organism |
|---|---|---|
| ? | x * 45000 + x * 66500, SDS-PAGE in presence of 2-mercaptoethanol | Homo sapiens |
Temperature Stability [°C]
| Temperature Stability Minimum [°C] | Temperature Stability Maximum [°C] | Comment | Organism |
|---|---|---|---|
| 60 | - |
30 min, 20% loss of activity | Homo sapiens |
| 70 | - |
15 min, 90% loss of activity | Homo sapiens |
pH Optimum
| pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
|---|---|---|---|
| 4.5 | 5.5 | with N-benzyloxycarbonyl-Pro-Phe, angiotensin II or angiotensin III as substrate | Homo sapiens |
pH Range
| pH Minimum | pH Maximum | Comment | Organism |
|---|---|---|---|
| 4.5 | 7 | - |
Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
